AUS
NZ
UK
CA
USA
IND
Highlights
- Neuren Pharmaceuticals (ASX:NEU) has secured a Type C meeting with the FDA to discuss efficacy endpoints for its Phase 3 trial of NNZ-2591.
- NNZ-2591 showed promising results in treating neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome.
- The company is preparing for a mid-year commencement of its first-ever Phase 3 trial for children with Phelan-McDermid syndrome.
Neuren Pharmaceuticals (ASX:NEU) has received confirmation for a Type C meeting with the U.S. Food and Drug Administration (FDA), scheduled for early April 2025. This meeting will focus on discussing the efficacy endpoints for the upcoming Phase 3 clinical trial of NNZ-2591, a drug candidate targeting multiple childhood neurodevelopmental disorders.
The upcoming Type C meeting follows a previous Type B End of Phase 2 meeting, during which critical aspects of the trial were reviewed and agreed upon. The discussions with the FDA will help shape the design and evaluation metrics for the Phase 3 program, ensuring that key regulatory requirements are met as the company advances its drug development efforts.
NNZ-2591 is Neuren’s second drug candidate, designed to address a range of genetic disorders affecting neurological development. During the Phase 2 clinical trial, the drug demonstrated positive therapeutic potential for conditions such as Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome. These disorders are characterized by intellectual disabilities, motor impairments, and speech deficits, significantly impacting the quality of life for affected individuals.
With a confirmed regulatory discussion in place, Neuren Pharmaceuticals is moving forward with preparations for the commencement of its first-ever Phase 3 trial for Phelan-McDermid syndrome. This milestone represents a crucial step in the development of NNZ-2591, as the company aims to establish its effectiveness and safety in a broader patient population.
Neuren Pharmaceuticals continues to advance its clinical pipeline, positioning itself as a key player in the development of innovative treatments for rare neurodevelopmental disorders. The engagement with the FDA is expected to provide valuable regulatory clarity, shaping the next phase of NNZ-2591’s clinical progress.
